从实验室到梳妆台，福瑞达廿载淬炼引领“液体黄金”蝶变

Core Insights - Shandong Furuida Pharmaceutical Co., Ltd. has been recognized for its project on "Key Technology and Industrialization Application of Biosynthetic Royal Jelly Acid," showcasing its strong research capabilities in synthetic biology [2][3] - The company has achieved a breakthrough in the biosynthesis of royal jelly acid, marking a significant step towards sustainable production and commercialization of this valuable ingredient [3][4] Group 1: Technological Breakthroughs - Furuida's royal jelly acid, known as 10-hydroxy-2-decenoic acid, is the first synthetic biological ingredient approved for cosmetics in China, enabling large-scale and green production [3][4] - The company has maintained a purity level of over 98% for its biosynthetic royal jelly acid, overcoming challenges associated with traditional extraction methods [4][5] - Furuida has filed seven invention patents related to this technology, establishing a solid technical barrier in the market [4] Group 2: Market Development - The launch of the "Jingyan Jinzhi" skincare line marks the entry of royal jelly acid into the consumer market, positioning it as a competitive product in the anti-aging skincare segment [5][6] - The skincare line is based on in-depth research into the mechanisms of royal jelly acid, demonstrating significant efficacy in skin barrier repair and anti-aging [5][6] - Furuida's brand, Aier Doctor, has achieved sales of 1 billion yuan within five years, solidifying its leadership in the domestic technology-driven skincare market [6] Group 3: Strategic Collaborations - Furuida has established long-term collaborations with various universities and research institutions, fostering a synergistic model of "enterprise posing questions, institutions providing solutions, and results being transformed" [7][8] - The company has created a transparent manufacturing process with 35 intelligent production lines, ensuring real-time monitoring and quality control [7][8] - Furuida's commitment to research and development has led to increased funding, enabling further advancements in synthetic biology and related technologies [8]